Endometrial Cancer Market on Track for Major Expansion by 2034, According to DelveInsight | AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott., ARIAD Pharmac

The Key Endometrial Cancer Companies in the market include - Eli Lilly, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others.

The Endometrial Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Endometrial Cancer pipeline products will significantly revolutionize the Endometrial Cancer market dynamics.

DelveInsight's "Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depthunderstanding of the Endometrial Cancer, historical and forecasted epidemiology as well as the Endometrial Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Endometrial Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Endometrial Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometrial Cancer Market Forecast [https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Endometrial Cancer Market Report:

*
The Endometrial Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In June 2025, Daiichi Sankyo has reported that the first patient has been dosed in the DESTINY-Endometrial01 clinical trial, which is assessing Enhertu (trastuzumab deruxtecan) in combination with either rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/2+), mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.

*
In May 2025, Kaida BioPharma revealed it has signed a manufacturing partnership with Northway Biotech, Inc., a full-service biologics Contract Development and Manufacturing Organization (CDMO), to produce its lead candidate, KAD101. This innovative biologic, a prolactin receptor antagonist, is currently being developed for platinum-resistant ovarian cancer (PROC), with potential to expand into the treatment of endometrial, uterine, and breast cancers.

*
In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed.

*
In May 2025, Combination therapies targeting the PI3K/AKT/mTOR and MAPK/ERK signaling pathways are currently being explored in the treatment of endometrial cancer. The mTOR inhibitors everolimus (Afinitor) and temsirolimus (Torisel) have been investigated in various combination regimens for patients with recurrent disease, aiming to disrupt these critical pathways involved in endometrial tumor development. Despite the evaluation of multiple doublet and triplet combinations, including those involving these agents, clinical outcomes have shown only modest effectiveness.

*
In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) have announced the dosing of the first patient in their Phase II combination trial involving PIKTOR-comprising FTH-001 (serabelisib) and FTH-003 (sapanisertib)-alongside paclitaxel. This study represents the most advanced effort to explore a novel dual PI3K-mTORC1/2 inhibition strategy aimed at targeting cancer metabolism in individuals with endometrial cancer.

*
The results from the Phase III RUBY trial, which focused on patients with primary advanced endometrial cancer (EC) showing mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H), were presented at the 2024 ASCO annual meeting.

*
According to the National Cancer Institute, approximately 3 in 100 women will be diagnosed with uterine cancer at some point in their lives

*
80 percent of people with uterine cancer survive for five years or longer after receiving the diagnosis. Endometrial cancer comprises about 4% of all cancers in women globally

*
According to the American cancer society, in the United States, the endometrium (the lining of the uterus) is the most common cancer of the female reproductive organs

*
As per Cancer Research UK, there are around 9,700new uterine cancer cases in the UK every year, that is 27 every day (2016-2018). Among females in the UK, uterine cancer is the 4th most common cancer,with around 9,700 new cases in 2017

*
According to the study by Aoki et al. ) 2020), about 380 000 new cases of endometrial cancer occur every year in the world, and about 89,000 deaths are confirmed annually. Endometrial cancer is the 10th most common cause of cancer in women in Japan, with more than 14,900 new patients diagnosed per year in recent years

*
Key Endometrial Cancer Companies: Eli Lilly, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others

*
Key Endometrial Cancer Therapies: Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others

Endometrial Cancer Overview

Endometrial cancer is a type of cancer that arises from the lining of the uterus, known as the endometrium. The endometrium is the tissue that typically undergoes changes during the menstrual cycle in preparation for pregnancy.

Get a Free sample for the Endometrial Cancer Market Report:

https://www.delveinsight.com/report-store/endometrial-cancer-market [https://www.delveinsight.com/report-store/endometrial-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometrial Cancer Market

The dynamics of the Endometrial Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

Endometrial Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometrial Cancer Epidemiology Segmentation:

The Endometrial Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Incident Cases of Endometrial Cancer in the 7MM

*
Stage-specific Cases of Endometrial Cancer in the 7MM

*
Age-specific Cases of Endometrial Cases in the 7MM

*
Drug Treatment Population by Line in the 7MM

Download the report to understand which factors are driving Endometrial Cancer epidemiology trends @ Endometrial Cancer Epidemiological Insights [https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometrial Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometrial Cancer market or expected to get launched during the study period. The analysis covers Endometrial Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endometrial Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Endometrial Cancer treatment, visit @ Endometrial Cancer Medications [https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Endometrial Cancer Therapies and Key Companies

*
Imlunestrant: Eli Lilly

*
Lynparza (Olaparib) + Imfinzi DuO-E: AstraZeneca

*
Selinexor: Karyopharm Therapeutics

*
EG-007: Evergreen Therapeutics

Endometrial Cancer Market Strengths

*
Significant developments during the last decade have altered the clinical management of patients with endometrial cancer and emphasized the need for standardized grossing and reporting of surgical resection specimens as well as morphologic assessment and ancillary testing for accurate classification of endometrial carcinomas.

Endometrial Cancer Market Opportunities

*
Emerging areas of therapeutic interest in the treatment of endometrial cancer lie in immunotherapy combinations, in DNA repair, and in incorporating molecular subgroups into clinical practice.

*
The treatment for endometrial cancer is rapidly evolving with the development of molecular analysis and novel strategies.

Scope of the Endometrial Cancer Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Endometrial Cancer Companies: AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others

*
Key Endometrial Cancer Therapies: Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others

*
Endometrial Cancer Therapeutic Assessment: Endometrial Cancer current marketed and Endometrial Cancer emerging therapies

*
Endometrial Cancer Market Dynamics: Endometrial Cancer market drivers and Endometrial Cancer market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Endometrial Cancer Unmet Needs, KOL's views, Analyst's views, Endometrial Cancer Market Access and Reimbursement

Discover more about therapies set to grab major Endometrial Cancer market share @ Endometrial Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/endometrial-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Endometrial Cancer Market Report Introduction

2. Executive Summary for Endometrial Cancer

3. SWOT analysis of Endometrial Cancer

4. Endometrial Cancer Patient Share (%) Overview at a Glance

5. Endometrial Cancer Market Overview at a Glance

6. Endometrial Cancer Disease Background and Overview

7. Endometrial Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Endometrial Cancer

9. Endometrial Cancer Current Treatment and Medical Practices

10. Endometrial Cancer Unmet Needs

11. Endometrial Cancer Emerging Therapies

12. Endometrial Cancer Market Outlook

13. Country-Wise Endometrial Cancer Market Analysis (2020-2034)

14. Endometrial Cancer Market Access and Reimbursement of Therapies

15. Endometrial Cancer Market Drivers

16. Endometrial Cancer Market Barriers

17. Endometrial Cancer Appendix

18. Endometrial Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=endometrial-cancer-market-on-track-for-major-expansion-by-2034-according-to-delveinsight-astrazeneca-karyopharm-therapeutics-evergreen-therapeutics-abbott-ariad-pharmac]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.